Orizal Plus (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Orizal Plus is a combination antihypertensive that acts on several pathways involved in blood pressure regulation.

• Hypertension: helps achieve target blood pressure when monotherapy does not provide adequate control.
• Hypertensive urgency: used as part of a regimen to lower blood pressure safely under medical supervision.
• Cardiovascular risk reduction: contributes to lowering the risk of stroke and heart attack in patients with high blood pressure.

• The three components work together: olmesartan medoxomil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide reduces sodium and water reabsorption in the distal tubules, decreasing plasma volume. The combined actions lower systemic vascular resistance and cardiac output, resulting in blood pressure reduction.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate headache may occur.
• Peripheral edema: swelling of the ankles or feet.
• Dizziness or light‑headedness, especially after the first doses.
• Fatigue: feeling unusually tired.
• Flushing: transient warmth or redness of the skin.
• Increased urination: due to the diuretic component.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Hyperkalemia: elevated potassium levels that may affect heart rhythm.
• Acute kidney injury: sudden decline in renal function.
• Angio‑edema: swelling of the face, lips, tongue or throat.
• Liver enzyme abnormalities: elevated ALT or AST.
• Blood disorders: neutropenia or thrombocytopenia.

When prescribing Orizal Plus, clinicians should consider several safety aspects.

• Renal impairment: dose adjustment may be needed in patients with reduced kidney function.
• Hepatic impairment: use cautiously in moderate to severe liver disease.
• Electrolyte disturbances: monitor potassium and sodium levels regularly.
• Pregnancy: avoid use unless clearly needed; discuss risks with a healthcare provider.
• Concomitant antihypertensives: risk of additive blood‑pressure lowering effects.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Orizal Plus can interact with a range of medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Aliskiren: combined use with an ARB may increase risk of renal impairment and hyperkalemia.
• Potassium‑rich supplements or salts: may cause dangerous hyper‑kalemia.
• NSAIDs (high‑dose): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

• Lithium: may increase lithium levels, requiring serum monitoring.
• CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine concentrations.
• Beta‑blockers: additive blood‑pressure lowering effect, monitor for symptomatic hypotension.